Endoscopic Balloon Dilation in IBD

Endoscopic balloon dilation (EBD) is a minimally invasive procedure used in the management of intestinal strictures in patients with inflammatory bowel disease (IBD), particularly Crohn’s disease (CD). Strictures are areas of narrowing in the gastrointestinal tract caused by inflammation, fibrosis, or a combination of both, which can lead to obstructive symptoms such as abdominal pain, bloating, and difficulty passing stool. EBD aims to widen these narrowed segments, thereby alleviating symptoms, avoiding surgical intervention, and improving patients' quality of life.

### Key Findings from the Study on EBD in IBD:

#### 1. **Definition of Difficult EBD**:

• EBD procedures were classified as "difficult" if they required more than three dilations per year without achieving satisfactory outcomes. These cases often involved technical challenges and poorer long-term results compared to easier cases.

#### 2. **Prevalence**:

• Difficult EBD accounted for **54.5%** of all procedures, whereas easier EBDs comprised **45.5%**.

#### 3. **Technical Success**:

• Easier EBDs achieved **100% surgery-free survival** beyond 12 months, compared to **97.4%** in difficult cases (P = 0.004). Despite good technical success rates, **17.3%** of patients eventually required surgery due to unsuccessful dilation outcomes.

#### 4. **Risk Factors for Difficult EBD**:

• **Smoking**: The strongest independent predictor of difficult EBD, with an odds ratio (OR) of **4.75** (95% CI 2.78–8.36; P < 0.001). Smoking cessation could significantly improve outcomes.
• **Prestenotic Dilation**: Associated with nearly **3-fold higher odds** of difficult EBD (OR 2.79; 95% CI 1.28–6.59; P = 0.013).
• **Balloon Diameter**: Smaller balloon sizes increased difficulty — each 1-mm decrease raised the risk (OR 1.21), while larger final diameters were protective (OR 0.68).
• **Medication Impact**:
• **Adalimumab (ADA)** and **Ustekinumab (UST)** therapies were linked to more difficult EBDs.
• **Vedolizumab (VDZ)** and immunosuppressive co-therapy (azathioprine, 6-MP, methotrexate) were associated with easier EBDs and improved outcomes.
• **Radiologic Predictors**:
• Presence of **multiple strictures** (35% vs 16.8%) and **prestenotic dilation** (14.3% vs 3.3%) were more frequent in difficult cases (P < 0.001).
• **Anatomic Pattern**:
• Ileocolonic phenotype (L3) and longer stricture lengths were more common in technically difficult dilations.
• **Age**:
• Younger age was associated with higher likelihood of difficult EBD (P < 0.001), possibly reflecting more aggressive disease behavior.
• **Crohn’s Disease Predominance**:
• The vast majority of difficult EBDs occurred in Crohn’s disease patients, confirming its fibrostenotic nature.

#### 5. **Protective Factors**:

• **Vedolizumab (VDZ)**: Demonstrated therapeutic protection and improved outcomes in EBD.
• **Immunosuppressive Co-therapy**: Use of azathioprine, 6-MP, or methotrexate was linked to easier EBDs.
• **Total Parenteral Nutrition (TPN)**: Showed a significant protective effect (OR 0.13; 95% CI 0.05–0.34; P < 0.001), likely due to its role in promoting mucosal healing.

#### 6. **Clinical Implications**:

• **Smoking Cessation**: Addressing smoking as a modifiable risk factor could reduce procedural difficulty and improve outcomes.
• **Medication Optimization**: Favoring therapies like Vedolizumab or combination immunosuppression may enhance success rates.
• **Improved Dilation Techniques**: Using larger balloon diameters and addressing prestenotic dilation could reduce procedural difficulty.
• **Tailored Therapy**: Individualized treatment plans based on patient characteristics (e.g., age, disease phenotype, and medication history) could lower surgical rates and healthcare costs.

#### 7. **Conclusion**:

• More than half of EBD procedures were classified as difficult, often requiring repeat interventions. Optimizing modifiable risk factors, tailoring therapy, and improving procedural techniques may enhance success, reduce surgical rates, and lower healthcare costs.

### Summary of EBD in IBD:

EBD represents an effective, surgery-sparing approach for managing strictures in IBD, especially Crohn’s disease. However, certain factors, such as smoking, smaller balloon diameters, and specific medication regimens, increase the risk of procedural difficulty. Protective strategies, including smoking cessation, Vedolizumab therapy, combination immunosuppression, and nutritional support like TPN, can improve outcomes. Careful patient selection and individualized treatment plans are essential to maximize the benefits of EBD while minimizing complications and the need for surgical intervention.